Video

Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease

It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

Transcript

How important is it for value assessments to take into account the unique factors of a disease state?

It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings. Of course the clinical benefit is incredibly important and it is still going to form the core of the actual value assessment. But, the context for which that therapy is actually being delivered is important because if a patient is perhaps receiving the very first therapy for their disease that they’ve ever been able to actually obtain, that is so much more important than perhaps a patient receiving a therapy for the first time but perhaps it’s the eight therapy or the ninth therapy for that disease. That first therapy is monumental. It’s revolutionary for the patient, as well as their families, their caregivers, really everyone who cares about them. So, that context is incredibly important to consider as health technology bodies are assessing the value of these therapies.

Related Videos
Drs Lillian L. Siu and Matthew G. Vander Heiden
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
AMCP Recap 2025
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo